Orchard Therapeutics plc (ORTX) News

Orchard Therapeutics plc (ORTX): $16.70

0.05 (+0.30%)

POWR Rating

Get Rating

Component Grades

Growth

Get Rating

Value

Get Rating

Momentum

D

Stability

D

Sentiment

Get Rating

Quality

D

Add ORTX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

NR

Ranked

#91 of NR

in industry
See All 'A' Rated Buy Stocks

Filter ORTX News Items

ORTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ORTX News From Around the Web

Below are the latest news stories about ORCHARD THERAPEUTICS PLC that investors may wish to consider to help them evaluate ORTX as an investment opportunity.

Orchard adds ~32% as FDA clears trial for metabolic disorder drug

  • Orchard Therapeutics (NASDAQ:ORTX) announced Thursday that the FDA cleared its Investigational New Drug (IND) application for OTL-203, targeted at the neurometabolic disease, Hurler subtype of mucopolysaccharidosis type I (MPS-IH).
  • Orchard (ORTX), a biotech focused on gene therapies, climbed ~32% pre-market in reaction. 
  • The company plans to evaluate OTL-203 against the standard of care in a global re...

    Seeking Alpha | January 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!